Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
Withdrawn before enrolling · Phase 1/Phase 2
Conditions studied: Carcinoma, Renal Cell, Melanoma
In brief
This study will evaluate the safety and disease control rate of the combination of pembrolizumab plus low-dose interleukin-2 in patients who have either advanced melanoma or renal cell cancer.
Key facts
- Study ID
- NCT03111901
- Run by
- William Grosh, MD
- People needed
- 0
- Starts
- 2018-10-29
- Expected to finish
- 2023-10-01
- Last updated by the study team
- 2019-07-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Virginia Cancer Center — Charlottesville, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.